Authors


Brett Watson, MD

Latest:

Management of UTUC using a kidney-sparing approach

Advances in endourology have made kidney-sparing treatments a viable treatment option.


Jason M. Hafron, MD, CMO

Latest:

Jason Hafron, MD, on PSMA-PET in oligometastatic disease

“Time will tell as we move forward, but it has allowed us to use MDT, with or without ADT and ARPIs, to potentially look at hormone-free treatments,” says Jason M. Hafron, MD, CMO.


Joshua Calvert, MD, MPH

Latest:

Robotics in GU oncology: Current status, future directions

The breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.

© 2025 MJH Life Sciences

All rights reserved.